CSL

@CSL

Since our start in 1916, we have been driven by our promise to identify, develop and deliver innovations so our patients can live life to the fullest.

Melbourne, Victoria

csl.com

Joined October 2015

2KPosts 6KFollowers 233Following

You might like

@ResAustralia

@The_VIIN

@GenCancerCentre

@EliLillyandCo

@WEHI_research

@PeterMacCC

@Macquarie

@QIMRB_Institute

@PeterMacRes

@EisaiUS

@Jlm_city

@SmallCapsDaily

@IYOBANKofficial

@AAMRI_Aus

CSL

@CSL

Oct 6

October is #PlasmaAwarenessMonth, an opportunity to thank our plasma donors for their generosity and to bring awareness of the important role that plasma plays in helping patients. Our plasma-derived therapies are made possible by the donation of plasma, and these therapies…

CSL's tweet image. October is #PlasmaAwarenessMonth, an opportunity to thank our plasma donors for their generosity and to bring awareness of the important role that plasma plays in helping patients.

Our plasma-derived therapies are made possible by the donation of plasma, and these therapies…

CSL

@CSL

Aug 18

Today we shared our full-year results for FY25. Take a look at some of the key financial and operational highlights. For more details visit our Investor Centre: investors.csl.com #CSL #FullYearResults

CSL

@CSL

Aug 8

The first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of #HAE has been authorized by Health Canada, offering those living with HAE a convenient administration approach. Read more: bit.ly/46MYCtN

CSL

@CSL

Jun 23

Applications for the 2026 CSL Centenary Fellowships will close on 30 June. We are inviting Australia’s top early-mid career scientists to apply for next year’s fellowships now. bit.ly/466kBez

CSL's tweet image. Applications for the 2026 CSL Centenary Fellowships will close on 30 June. We are inviting Australia’s top early-mid career scientists to apply for next year’s fellowships now. bit.ly/466kBez

CSL

@CSL

Jun 18

Innovation meets convenience with our first homegrown mAb to gain approval, offering a new option that may help patients manage their condition. We’re proud to bring this innovation to the HAE community. bit.ly/4jZZuOH

CSL's tweet image. Innovation meets convenience with our first homegrown mAb to gain approval, offering a new option that may help patients manage their condition. We’re proud to bring this innovation to the HAE community. bit.ly/4jZZuOH

CSL reposted

Elizabeth Day 🇦🇺

@AusAmbCH

Jun 13

@CSL Behring exemplifies the enduring #partnership between Australia and Switzerland, merging Australian #innovation with Swiss precision. It was a pleasure to attend the 25th Anniversary of CSL Behring celebrations in Bern yesterday. @CSLVifor

AusAmbCH's tweet image. @CSL Behring exemplifies the enduring #partnership between Australia and Switzerland, merging Australian #innovation with Swiss precision.

It was a pleasure to attend the 25th Anniversary of CSL Behring celebrations in Bern yesterday.

@CSLVifor

CSL

@CSL

Jun 17

The U.S. FDA has approved the only once-monthly treatment targeting factor XIIa to prevent attacks of HAE. This reflects our commitment to HAE patients around the world, a community we have proudly supported for over four decades. Read more: bit.ly/3FFkoEI.

CSL's tweet image. The U.S. FDA has approved the only once-monthly treatment targeting factor XIIa to prevent attacks of HAE. This reflects our commitment to HAE patients around the world, a community we have proudly supported for over four decades. Read more: bit.ly/3FFkoEI.

CSL

@CSL

Jun 9

Dr @qizhang85 from @SAiGENCI, @UniofAdelaide is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: bit.ly/3FxGI2Z

CSL

@CSL

May 26

.@DrClareWeeden from @WEHI_research is doing important #research with the support of a #CSLCentenaryFellowship. Applications for 2026 are now open: bit.ly/3SmhVS7 #CSL

CSL

@CSL

May 11

Applications are open for the 2026 CSL Centenary Fellowships. Australian early-mid career biomedical #researchers are invited to apply for 1 of 2 A$1.25m #grants over 5 years. bit.ly/4mcIkzk

CSL's tweet image. Applications are open for the 2026 CSL Centenary Fellowships. Australian early-mid career biomedical #researchers are invited to apply for 1 of 2 A$1.25m #grants over 5 years. bit.ly/4mcIkzk

CSL

@CSL

Apr 23

Congratulations to the eight medical researchers who have been awarded a CSL Research Acceleration Initiative (RAI) partnership to fast-track the discovery of innovative biotherapies to address unmet medical needs. bit.ly/4cLXPKw

CSL's tweet image. Congratulations to the eight medical researchers who have been awarded a CSL Research Acceleration Initiative (RAI) partnership to fast-track the discovery of innovative biotherapies to address unmet medical needs. bit.ly/4cLXPKw

CSL

@CSL

Apr 22

CSL is proud to sponsor the symposium "WHO guidance on PBM implementation: Strategies for effective dissemination and communication" at @NATAforum. We look forward to welcoming you on Thursday 24 April at 12:15 CET!

CSL's tweet image. CSL is proud to sponsor the symposium "WHO guidance on PBM implementation: Strategies for effective dissemination and communication" at @NATAforum. We look forward to welcoming you on Thursday 24 April at 12:15 CET!

CSL

@CSL

Feb 20

Japan’s MHLW approved our first-in-class monoclonal antibody for HAE, reinforcing our commitment to a community we have supported for more than 40 years. Japan joins Australia, the UK, and the EU in offering an innovative treatment to patients. Learn more: bit.ly/4bqvtVD

CSL's tweet image. Japan’s MHLW approved our first-in-class monoclonal antibody for HAE, reinforcing our commitment to a community we have supported for more than 40 years. Japan joins Australia, the UK, and the EU in offering an innovative treatment to patients. Learn more: bit.ly/4bqvtVD

CSL

@CSL

Feb 19

The European Commission’s approval of our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE reflects our ongoing commitment to improving the lives of people living with this condition.

CSL's tweet image. The European Commission’s approval of our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE reflects our ongoing commitment to improving the lives of people living with this condition.

CSL

@CSL

Feb 14

Along with our partner @ArcturusRx, we are proud to announce that the EC has approved the first self-amplifying mRNA COVID-19 vaccine in the European Union. Read more: bit.ly/47HgF1z.

CSL's tweet image. Along with our partner @ArcturusRx, we are proud to announce that the EC has approved the first self-amplifying mRNA COVID-19 vaccine in the European Union. Read more: bit.ly/47HgF1z.

CSL

@CSL

Feb 13

Our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE is approved by the EC. We are committed to advancing care for people living with HAE, a community we have supported for over 40 years. Read more: bit.ly/47HgF1z.

CSL's tweet image. Our first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks of HAE is approved by the EC. We are committed to advancing care for people living with HAE, a community we have supported for over 40 years. Read more: bit.ly/47HgF1z.

CSL

@CSL

Feb 10

Our CEO and Managing Director Paul McKenzie discusses some of the highlights from our half-year results for financial year 2025. For the full presentation, including disclaimers & notes supporting financial information, visit our investor centre: bit.ly/3Q9WouX #CSL

CSL

@CSL

Feb 10

Today we shared our results for the first half of the 2025 financial year. Below is a snapshot of the financial and operational highlights. You can find more details at our investor centre: bit.ly/4hsQPUv #CSL

CSL's tweet image. Today we shared our results for the first half of the 2025 financial year. Below is a snapshot of the financial and operational highlights. You can find more details at our investor centre: bit.ly/4hsQPUv #CSL

CSL

@CSL

Jan 28

Our first approved homegrown recombinant mAb highlights our unwavering dedication to advancing care for those with HAE – a community we have supported for over 40 years. We are committed to improving the lives of patients around the world. Read more: bit.ly/4awYH4o.

CSL's tweet image. Our first approved homegrown recombinant mAb highlights our unwavering dedication to advancing care for those with HAE – a community we have supported for over 40 years. We are committed to improving the lives of patients around the world. Read more: bit.ly/4awYH4o.

CSL

@CSL

Jan 23

We are proud to announce that Australia’s TGA has approved the first and only once-monthly treatment targeting factor XIIa to prevent attacks of #HAE. Read more: bit.ly/4htSbh6